Osteoarthritis pain in cats: frunevetmab vs placebo — LIKELY

In cats with osteoarthritis pain, does monthly subcutaneous frunevetmab improve owner-assessed pain and activity scores vs placebo?

Shelf #195 · gate-verified and displayed under the developer's blinded-trial rule

LIKELY: Monthly frunevetmab improves owner-assessed osteoarthritis pain in cats versus placebo. In the pivotal trial (275 cats), frunevetmab beat placebo on the client-specific outcome measures questionnaire at days 28 and 56 (standardized effect size 0.3 and number needed to treat of 9 at day 56), on owner-assessed global treatment response at days 28 and 56, and on veterinarian-assessed joint pain at days 56 and 84 (effect size 0.18 at day 56). A smaller pilot field study (126 cats) pointed the same way, with owner-rated mobility improving over placebo at days 42 and 56. The effects are real but modest in size, skin disorders occurred more often on frunevetmab in the pivotal trial (32/182 vs 8/93 cats), and both trials were manufacturer-linked — the stamp is LIKELY, not higher. Drafted Nov 10, 2026 (VetMed build, topic #195); all figures from abstracts fetched and verified at drafting.

Gruen 2021: frunevetmab beat placebo on owner-assessed OA pain scores at days 28 and 56 in 275 cats

Randomized, placebo-controlled, parallel-group, double-blind superiority study

Who: Cats: 275 client-owned cats with naturally-occurring osteoarthritis pain and associated mobility impairment and disability; 182 received frunevetmab (nominal dose 1.0 mg/kg SC, effective dose range 1.0-2.8 mg/kg) and 93 placebo, on days 0, 28 and 56.

Result: Significant improvement with frunevetmab over placebo occurred at days 28 and 56 for the client specific outcome measures (CSOM) questionnaire (success rates and total scores; number needed to treat of 9 and standardized effect size of 0.3 at day 56), at days 28 and 56 for owner-assessed global treatment response, and at days 56 and 84 for veterinarian-assessed joint pain (effect size of 0.18 at day 56). Adverse events did not differ between groups except skin disorders, which collectively occurred significantly more frequently in frunevetmab-treated cats (32/182) vs placebo (8/93).

Watch out: Outcomes are owner- and veterinarian-assessed scores, not objective activity measures, and effect sizes are modest (0.3 and 0.18). Authors include the manufacturer's (Zoetis) research group.

Gruen ME, Myers JAE, Tena JS et al. Frunevetmab, a felinized anti-nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats. J Vet Intern Med. 2021;35(6):2752-2762. PMID: 34724255. Registry ID: none in the record. MeSH: Animals · Antibodies, Monoclonal · Cat Diseases · Cats · Double-Blind Method · Osteoarthritis · Pain · Surveys and Questionnaires · Treatment Outcome

Gruen 2021 (pilot): frunevetmab improved owner ratings of mobility over placebo at days 42 and 56 in 126 cats

Randomized placebo-controlled, double-masked pilot field study

Who: Cats: 126 cats with degenerative joint disease-associated chronic pain in a multisite pilot field study; randomized to frunevetmab IV then SC (n=42), frunevetmab SC then SC (n=43), or placebo IV then SC (n=41), on days 0 and 28, after a week-long pain and activity baseline.

Result: Owner questionnaire results showed significant improvement in frunevetmab-treated cats compared to placebo (p < 0.05) at days 42 and 56, with no difference between routes of administration. All groups had decreased objectively measured weekly activity from baseline: frunevetmab-treated cats had a mean decrease of 0.9%, while placebo-treated cats had a mean decrease of 9.3%. Treatments were generally well tolerated; dermatitis/alopecia related to activity-monitor collars occurred in a higher percentage of frunevetmab than placebo cats.

Watch out: A pilot study, and its objective accelerometry measure fell in both groups — the owner-rating benefit is not backed by an increase in measured activity. This record carries no MeSH indexing.

Gruen ME, Myers JAE, Lascelles BDX. Efficacy and Safety of an Anti-nerve Growth Factor Antibody (Frunevetmab) for the Treatment of Degenerative Joint Disease-Associated Chronic Pain in Cats: A Multisite Pilot Field Study. Front Vet Sci. 2021;8:610028. PMID: 34124212. Registry ID: none in the record. MeSH: none in the record

Synthesis: a real but modest owner-assessed benefit, with a skin-disorder signal to watch

Synthesis

Who: Synthesis of the cards above: Gruen 2021 pivotal trial (randomized, double-blind, placebo-controlled, 275 cats) and Gruen 2021 pilot field study (randomized, double-masked, placebo-controlled, 126 cats).

Result: Two randomized, blinded, placebo-controlled trials agree that monthly frunevetmab improves owner-assessed pain and mobility in cats with osteoarthritis versus placebo. The size of the benefit is modest (effect size 0.3 on the main owner questionnaire; number needed to treat of 9), objective activity did not rise, and skin disorders were more frequent on treatment in the pivotal trial (32/182 vs 8/93). That combination — consistent direction, small-to-moderate effect, subjective primary measures — is what carries the LIKELY stamp.

Watch out: Both trials are linked to the product's manufacturer (Zoetis authors on the pivotal trial), and neither runs beyond 84 days, so long-term safety and durability rest on post-marketing experience, not on these cards.

Synthesis of Gruen ME et al. PMID: 34724255; Gruen ME et al. PMID: 34124212. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.